New York Presbyterian is purchasing additional WasteLog® systems as part of an expanded Drug Diversion Prevention Program. After installation, New York Presbyterian will have a total of 9 WasteLog® systems.
New York Presbyterian (NYP), one of the US’s most prestigious integrated academic health care delivery systems with 10 hospital campuses located in the greater New York metropolitan area, chose in April 2019 to invest a total of 5 WasteLog® units for its facilities located in the 5 boroughs of New York. The systems have been used to verify that returned narcotic drugs have not been replaced or tampered with and are part of NYP’s Drug Diversion Prevention Program. In June this year the program expanded to the Greater New York facilities with the purchase of 3 additional WasteLog® systems for placement at Hudson Valley, Lawrence & Allen hospitals.
NYP has now signed an agreement for another WasteLog® system to be placed at the brand-new Brooklyn Methodist Center for Community Health (CCH), a 400,000 square-foot state of the art multispecialty outpatient facility. The agreement is entered directly with Pharmacolog Inc. and is estimated to generate income corresponding to SEK 400,000 over a period of two years.
CEO, Mats Högberg comments: “We are extremely proud that NYP once again gives us the opportunity to be part of the organizations initiative to prevent Drug Diversion. The agreement we signed with NYP just over two years ago was our breakthrough order into the US market and has been of great importance for our expansion in North America. It’s so gratifying to see that NYP chose to expand the program to all nine facilities with surgical services.”
This information is insider information that Pharmacolog AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on October 19, at 08:30.
About Pharmacolog AB
Pharmacolog is specialized in developing systems and solutions for more effective and safer use of intravenous drugs. The company’s first product, DrugLog®, enables a nurse or pharmacist to quickly and easily verify that an injectable drug has the right identity and concentration. Pharmacolog’s long-term vision is an individually optimized medication for each individual patient, considering all available parameters in the control and distribution of the drug. Further information regarding the company is available at http://www.pharmacolog.com. The company’s Certified Adviser is Mangold Fondkommission AB, which can be reached on telephone number +46 8-5030 15 50 or through CA@mangold.se.